MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 79 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $5,723,000 | +49.2% | 2,253,118 | +19.3% | 0.29% | -86.5% |
Q1 2020 | $3,835,000 | -34.2% | 1,889,100 | -30.0% | 2.17% | +138.0% |
Q4 2019 | $5,832,000 | -8.5% | 2,700,000 | -34.8% | 0.91% | -8.8% |
Q3 2019 | $6,377,000 | -61.0% | 4,140,819 | +5.1% | 1.00% | -9.4% |
Q2 2019 | $16,354,000 | +1.7% | 3,940,819 | +2.5% | 1.10% | -29.2% |
Q1 2019 | $16,074,000 | +31.5% | 3,845,407 | -9.7% | 1.56% | -37.1% |
Q4 2018 | $12,224,000 | -44.1% | 4,259,367 | +94.7% | 2.47% | +70.4% |
Q3 2018 | $21,874,000 | +11.3% | 2,187,367 | -21.3% | 1.45% | -17.6% |
Q2 2018 | $19,650,000 | +61.3% | 2,779,321 | -12.8% | 1.76% | +49.4% |
Q1 2018 | $12,179,000 | -34.5% | 3,188,221 | +39.9% | 1.18% | -35.3% |
Q4 2017 | $18,595,000 | +18.0% | 2,278,848 | -15.1% | 1.82% | -45.2% |
Q3 2017 | $15,760,000 | +1401.0% | 2,684,848 | +250.3% | 3.32% | +1181.9% |
Q2 2017 | $1,050,000 | -23.5% | 766,448 | -1.1% | 0.26% | -36.8% |
Q1 2017 | $1,372,000 | – | 775,000 | – | 0.41% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 5,042,735 | $14,473,000 | 4.95% |
VHCP Management III, LLC | 1,258,964 | $3,613,000 | 2.63% |
Granite Point Capital Management, L.P. | 2,659,367 | $7,632,000 | 1.54% |
Granite Point Capital Management, L.P. | 1,600,000 | $4,592,000 | 0.93% |
VHCP Management II, LLC | 743,876 | $2,135,000 | 0.92% |
Monashee Investment Management LLC | 250,000 | $718,000 | 0.49% |
683 Capital Management, LLC | 1,350,000 | $3,875,000 | 0.24% |
CAXTON CORP | 61,443 | $176,000 | 0.21% |
Tekla Capital Management LLC | 755,776 | $2,169,000 | 0.09% |
Fosun International Ltd | 491,997 | $1,378,000 | 0.08% |